NEW HAVEN, Conn., Sept. 17, 2007 (PRIME NEWSWIRE) -- Achillion Pharmaceuticals, Inc., (Nasdaq:ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Chief Executive Officer of Achillion, will present a corporate overview and update on the Company's clinical programs in HIV, HCV and serious bacterial infections at the First Annual Maxim Group Growth Conference. The Company presentation will take place on Thursday, September 20, 2007 at 8:30 a.m. EST at the Grand Hyatt Hotel, New York.
The live audio broadcast and the subsequent archived webcast of the Company presentation will be available on the Company's website, www.achillion.com, under the "Investors" section. The audio recording will be archived there for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.
Achillion is a biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for infectious diseases. Achillion is currently developing treatments for HIV infection, chronic hepatitis C infection and serious hospital-based bacterial infections. For more information on Achillion Pharmaceuticals, please visit the company's web site at www.achillion.com or call Achillion at 1-203-624-7000. ACHN-G
CONTACT: Achillion Pharmaceuticals, Inc Mary Kay Fenton (203) 624-7000 firstname.lastname@example.org MacDougall Biomedical Communications Media: Kari Watson (508) 647-0209 email@example.com